HZNP Horizon Therapeutics Public Ltd Co

  1. Stocks
  2. Healthcare
  3. NASDAQ: HZNP

Price (delayed)

$108.52

Market cap

$24.79B

P/E Ratio

47.6

Dividend/share

N/A

EPS

$2.28

Enterprise value

$25B

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise ...

Highlights
Horizon Therapeutics's quick ratio has increased by 28% YoY
Horizon Therapeutics's revenue has increased by 12% YoY
HZNP's gross profit is up by 11% year-on-year but it is down by 2.6% since the previous quarter
The stock's price to earnings (P/E) is 51% more than its last 4 quarters average of 31.5 and 33% more than its 5-year quarterly average of 35.8
Horizon Therapeutics's EPS has decreased by 9% from the previous quarter and by 3.8% YoY
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.horizontherapeutics.com
Peers: AMGN MRK PFE

Key stats

What are the main financial stats of HZNP
Market
Shares outstanding
228.45M
Market cap
$24.79B
Enterprise value
$25B
Valuations
Price to earnings (P/E)
47.6
Price to book (P/B)
4.85
Price to sales (P/S)
6.85
EV/EBIT
40.93
EV/EBITDA
24.97
EV/Sales
6.89
Earnings
Revenue
$3.63B
EBIT
$610.64M
EBITDA
$1B
Free cash flow
$1.19B
Per share
EPS
$2.28
Free cash flow per share
$5.21
Book value per share
$22.38
Revenue per share
$15.84
TBVPS
$23.74
Balance sheet
Total assets
$9.11B
Total liabilities
$4.04B
Debt
$2.56B
Equity
$5.07B
Working capital
$2.7B
Liquidity
Debt to equity
0.51
Current ratio
3.85
Quick ratio
3.2
Net debt/EBITDA
0.21
Margins
EBITDA margin
27.6%
Gross margin
74.6%
Net margin
14.4%
Operating margin
16.9%
Efficiency
Return on assets
5.8%
Return on equity
10.5%
Return on invested capital
12.7%
Return on capital employed
7.5%
Return on sales
16.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HZNP stock price

How has the Horizon Therapeutics stock price performed over time
Intraday
0.67%
1 week
-0.5%
1 month
-1.79%
1 year
-1.17%
YTD
-4.64%
QTD
-4.64%

Financial performance

How have Horizon Therapeutics's revenue and profit performed over time
Revenue
$3.63B
Gross profit
$2.71B
Operating income
$611.85M
Net income
$521.48M
Gross margin
74.6%
Net margin
14.4%
The company's net margin fell by 13% YoY and by 7% QoQ
Horizon Therapeutics's revenue has increased by 12% YoY
The operating income has increased by 12% year-on-year but it has declined by 9% since the previous quarter
HZNP's gross profit is up by 11% year-on-year but it is down by 2.6% since the previous quarter

Growth

What is Horizon Therapeutics's growth rate over time

Valuation

What is Horizon Therapeutics stock price valuation
P/E
47.6
P/B
4.85
P/S
6.85
EV/EBIT
40.93
EV/EBITDA
24.97
EV/Sales
6.89
The stock's price to earnings (P/E) is 51% more than its last 4 quarters average of 31.5 and 33% more than its 5-year quarterly average of 35.8
Horizon Therapeutics's EPS has decreased by 9% from the previous quarter and by 3.8% YoY
HZNP's price to book (P/B) is 24% higher than its 5-year quarterly average of 3.9 and 15% higher than its last 4 quarters average of 4.2
The equity is up by 9% year-on-year
HZNP's price to sales (P/S) is 25% more than its 5-year quarterly average of 5.5 and 22% more than its last 4 quarters average of 5.6
Horizon Therapeutics's revenue has increased by 12% YoY

Efficiency

How efficient is Horizon Therapeutics business performance
HZNP's ROE is down by 16% YoY and by 11% from the previous quarter
HZNP's return on invested capital is up by 13% year-on-year but it is down by 9% since the previous quarter
Horizon Therapeutics's return on assets has decreased by 11% QoQ and by 9% YoY
Horizon Therapeutics's ROS has decreased by 7% from the previous quarter

Dividends

What is HZNP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HZNP.

Financial health

How did Horizon Therapeutics financials performed over time
The total assets is 125% more than the total liabilities
Horizon Therapeutics's quick ratio has increased by 28% YoY
Horizon Therapeutics's current ratio has increased by 22% YoY but it has decreased by 2.8% QoQ
The company's debt is 49% lower than its equity
The equity is up by 9% year-on-year
The debt to equity has declined by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.